/GMT.WA

GMT.WA Stock - Genomtec S.A.

Q: What is the analyst price target for GMT.WA?

Analyst price target information is not currently available for GMT.WA.

Q: What is GMT.WA's market cap?

Market capitalization information is not currently available for GMT.WA.

Healthcare|Medical - Devices|WSE

$3.77+4.72%

+$0.17 (+4.72%) • Dec 23

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $4.15

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for GMT.WA

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.16

52W High$8.59

52W Low$3.25

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$1,000	$1,000	$40,000	$219,000	$20,000
Gross Profit	$1,000	$-793,000	$-817,000	$-376,000	$-228,000
Gross Margin	100.0%	-79300.0%	-2042.5%	-171.7%	-1140.0%
Operating Income	$-11,055,000	$-8,727,000	$-11,953,000	$-10,540,000	$-14,481,000
Net Income	$-11,208,000	$-9,013,000	$-11,928,000	$-7,115,000	$-10,939,000
Net Margin	-1120800.0%	-901300.0%	-29820.0%	-3248.9%	-54695.0%
EPS	$-0.84	$-0.74	$-1.27	$-0.87	$-1.34

Company Overview

Genomtec S.A. researches, develops, manufactures, and commercializes innovative molecular diagnostic products in optical systems and isothermal nucleic acid amplification methods in Poland and internationally. The company develops Genomtec ID, a technological device that offer mobile genetic diagnosis to patients through streamlined nucleic acid amplification technology (SNAAT) to detect viruses, bacteria, and fungi, as well as genetic mutations by analyzing the biological material of patients using swabs, urine samples, saliva, blood, and other body fluids. It also develops Genomtec Tumor, a SNAAT based solution used to identify neoplastic mutations and mutations with prognostic value in neoplastic disease; Genomtec SARS-CoV-2 EvaGreen and Direct-RT-LAMP CE-IVD Kit to detect SARS-CoV-2 RNA in various biological samples from patients with suspected COVID-19 infection; and Genomtec RT-LAMP CE-IVD Duo-Kit for the detection of all variants of the SARS-CoV-2 virus. Genomtec S.A was founded in 2016 and is based in Wroclaw, Poland.

Visit Website